RxDoctor Payments Data

Sharon Mitchell, MD

Internal Medicine · Baldwyn, MSNPI 1306806930

Payments from drug & device makers

$944in general payments, 2019–2025

Across 39 payments — averaging $24.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$310
  • Stemline Therapeutics Inc.$125
  • Novo Nordisk$122
  • AbbVie$55
  • Sunovion Pharmaceuticals Inc.$54
  • Amgen$46
  • plus $232 from 11 others

What the payments were for

  • Food & beverage$944100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$944 in reported general payments places this provider in the 60th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$152,030
Medicare patients
195
Services billed
5,650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide89$106,493
JardianceEmpagliflozin76$73,080
MounjaroTirzepatide29$35,344
TradjentaLinagliptin45$34,473
JanuviaSitagliptin Phosphate32$23,366
FarxigaDapagliflozin Propanediol18$17,824
LinzessLinaclotide23$13,324
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen380$8,336
EliquisApixaban14$8,063
SynjardyEmpagliflozin/Metformin Hcl11$6,437
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$4,563
Humalog Mix 75-25Insulin Lispro Protamin/Lispro16$4,132
Gabapentin270$3,831
Novolog FlexpenInsulin Aspart19$3,823
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$3,110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Synjardy$20$113,989132 claims
Novo NordiskOzempic$122$106,49389 claims
AstraZenecaFarxiga$310$17,82418 claims
AbbVieLinzess, Synthroid$55$14,47435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Baldwyn

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →